Home › Compare › SPHRF vs MCD

SPHRF vs MCD: Dividend Comparison 2026

SPHRF yields 606.06% · MCD yields 2.34%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SPHRF wins by $280371.09M in total portfolio value
10 years
SPHRF
SPHRF
● Live price
606.06%
Share price
$0.33
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$280371.17M
Annual income
$211,667,981,687.60
Full SPHRF calculator →
MCD
McDonald's Corporation
● Live price
2.34%
Share price
$310.79
Annual div
$7.26
5Y div CAGR
42.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$77.7K
Annual income
$25,833.37
Full MCD calculator →

Portfolio growth — SPHRF vs MCD

📍 SPHRF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSPHRFMCD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SPHRF + MCD cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
SPHRF pays
MCD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SPHRF
Annual income on $10K today (after 15% tax)
$51,515.15/yr
After 10yr DRIP, annual income (after tax)
$179,917,784,434.46/yr
MCD
Annual income on $10K today (after 15% tax)
$198.56/yr
After 10yr DRIP, annual income (after tax)
$21,958.36/yr
At 15% tax rate, SPHRF beats the other by $179,917,762,476.10/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SPHRF + MCD for your $10,000?

SPHRF: 50%MCD: 50%
100% MCD50/50100% SPHRF
Portfolio after 10yr
$140185.62M
Annual income
$105,834,003,760.49/yr
Blended yield
75.50%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MCD right now

SPHRF
No analyst data
Altman Z
11.2
Piotroski
3/9
MCD
Analyst Ratings
37
Buy
23
Hold
1
Sell
Consensus: Buy
Price Target
$351.76
+13.2% upside vs current
Range: $320.00 — $385.00
Altman Z
4.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SPHRF buys
0
MCD buys
0
No recent congressional trades found for SPHRF or MCD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSPHRFMCD
Forward yield606.06% ✓2.34%
Annual dividend / share$2.00$7.26 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%42.3% ✓
Portfolio after 10y$280371.17M ✓$77.7K
Annual income after 10y$211,667,981,687.60 ✓$25,833.37
Total dividends collected$274648.71M ✓$57.7K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary

Year-by-year: SPHRF vs MCD ($10,000, DRIP)

YearSPHRF PortfolioSPHRF Income/yrMCD PortfolioMCD Income/yrGap
1← crossover$71,306$60,606.06$10,812$332.41+$60.5K → SPHRF
2$480,183$403,885.93$11,819$488.02+$468.4K → SPHRF
3$3,055,680$2,541,883.57$13,111$724.37+$3.04M → SPHRF
4$18,386,820$15,117,242.14$14,832$1,091.05+$18.37M → SPHRF
5$104,687,331$85,013,433.96$17,219$1,675.85+$104.67M → SPHRF
6$564,382,839$452,367,394.46$20,688$2,641.85+$564.36M → SPHRF
7$2,883,114,581$2,279,224,943.60$25,990$4,309.70+$2883.09M → SPHRF
8$13,966,501,456$10,881,568,854.67$34,590$7,351.77+$13966.47M → SPHRF
9$64,208,586,900$49,264,430,341.75$49,535$13,285.25+$64208.54M → SPHRF
10$280,371,169,670$211,667,981,687.60$77,746$25,833.37+$280371.09M → SPHRF

SPHRF vs MCD: Complete Analysis 2026

SPHRF — Stock

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. It offers VivaGel, a non-antibiotic therapy for the treatment and prevention of bacterial vaginosis. The company also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray. In addition, it develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase 2 clinical trials, DEP cabazitaxel that is in Phase 2 clinical trial, DEP gemcitabine that is in a Phase 1/2 clinical trials, and DEP irinotecan that is in Phase 2 clinical trials for the treatment of cancer; DEP radiotheranostics for cancer treatment and diagnosis; DEP Antibody Drug Conjugates; DEP HER-2 ADC; DEP non-oncology candidates; and DEP AZD0466, which is in Phase 1/2 clinical trials to treat haematological malignancies. The company was founded in 1996 and is headquartered in Abbotsford, Australia.

Full SPHRF Calculator →

MCD — Consumer Discretionary

McDonald's Corporation operates and franchises McDonald's restaurants in the United States and internationally. Its restaurants offer hamburgers and cheeseburgers, chicken sandwiches and nuggets, wraps, fries, salads, oatmeal, shakes, desserts, sundaes, soft serve cones, bakery items, soft drinks, coffee, and beverages and other beverages, as well as breakfast menu, including biscuit and bagel sandwiches, breakfast burritos, hotcakes, and other sandwiches. As of December 31, 2021, the company operated 40,031 restaurants. McDonald's Corporation was founded in 1940 and is headquartered in Chicago, Illinois.

Full MCD Calculator →
📬

Get this SPHRF vs MCD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SPHRF vs SCHDSPHRF vs JEPISPHRF vs OSPHRF vs KOSPHRF vs MAINSPHRF vs YUMSPHRF vs QSRSPHRF vs SBUX

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.